FeesSafety
Pluang+

CEO.CA shares exclusive insights with junior mining CEOs, featuring Galantas Gold's CEO on their growth in Chile.

Market News
14 Sep 2026
Newsfile Corp
View Source
Bullish
CEO.CA shares exclusive insights with junior mining CEOs, featuring Galantas Gold's CEO on their growth in Chile.

CEO.CA, a leading investor social network for junior resource stocks, provides exclusive interviews with CEOs of junior mining companies. Recently, CEO Mario Stifano of Galantas Gold Corp. discussed the company's rapid development into a multi-asset gold producer in Chile. CEO.CA connects millions of investors globally and offers in-depth coverage of emerging mining companies and industry leaders. Investors can access these insights via CEO.CA's website and app, enhancing their understanding of the junior mining sector's evolving landscape.

Galantas Gold's development plans provide context for the Basic Materials sector's market activity. For readers following this sector, here is Pluang's market snapshot as of Sep 14, 2026 20:12 WIB: Among 32 priced US Basic Materials stocks, 8 rose and 23 fell. Notable prices include Wheaton Precious Metals Corp at USD 148.80 (-3.45%), Barrick Gold Corp at USD 42.19 (-3.41%), and Newmont Corporation at USD 122.61 (-3.31%).

More News

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
2 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
2 hours ago
New Proof of Human feature links Alien ID to Solana wallets for real user verification.

New Proof of Human feature links Alien ID to Solana wallets for real user verification.

A new Proof of Human feature allows users to link an Alien ID to any Solana wallet, verifying that a real person controls the wallet. This initiative aims to enhance trust and security in blockchain transactions by confirming human identity behind wa...

Protocol Fundamentals
Neutral
4 hours ago
Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

Perioperative apalutamide plus ADT cuts risk of prostate cancer recurrence or death by 62% versus surgery alone

New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...

Market News
Bullish
4 hours ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App